Serum Uric Acid and Hemoglobin Levels as Prognostic Factors for COVID-19 Disease in Lung Cancer Patients Serum Uric Acid and Hemoglobin Levels
Article Sidebar
Main Article Content
Abstract
Objective: Cancer patients have a higher risk of COVID-19 infection compared to the healthy population. Therefore, the aim of this study is to assess the parameters and inflammatory indices that influence mortality in lung cancer patients who contract COVID-19.
Material and Methods: The sample of this single-center retrospective study comprised 66 patients diagnosed with lung cancer and treated for COVID-19 between April 2020 and July 2021. The neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, prognostic index, modified Glasgow prognostic score, and COVID inflammatory score were calculated for all patients. A total of twenty-seven potential prognostic variables were identified for further analysis through univariate and multivariate analyses.
Results: Seven variables with statistically significant prognostic values were identified as a result. The identified variables include having received chemotherapy in the last 28 days, hospitalization in the intensive care unit, the need for mechanical ventilation, receipt of COVID-19 corticosteroid treatment, serum uric acid level, hemoglobin level, and platelet count. The seven variables with prognostic value were subjected to Cox regression analysis. The results of the multivariate logistic regression analysis indicated that low hemoglobin and low uric acid levels emerged as independent risk factors for survival in lung cancer patients infected with COVID-19.
Conclusion: To the best of our knowledge, this is the first study to suggest that serum hemoglobin levels less than 10 g/dL and serum uric acid levels less than 3.5 mg/dL can serve as prognostic factors in lung cancer patients infected with COVID-19, aiding in predicting mortality.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2023-07-28
Published 2023-07-30
References
Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male 2020;23(5):1416-24.
Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov 2020;10(6):783-91.
Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol 2020;92(10):2067-73.
Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21(3):335-7.
Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardeset M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med 2020;26(8):1218-23.
Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol 2020;21(7):914-22.
Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020;20(6):363-74.
Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 2020;8(6):e46-e7.
Arnaldez FI, O'Day SJ, Drake CG, Fox BA, Fu B, Urba VJ, et al. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. J Immunother Cancer 2020;8(1).
Moses AG, Maingay J, Sangster K, Fearon KC, Ross JA. Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol Rep 2009;21(4):1091-5.
Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15(2):74-80.
Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013;88(1):218-30.
Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012;17(3):216-22.
Sun K, Chen S, Xu J, Li G, He Y. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2014;140(9):1537-49.
Sanghera C, Teh JJ, Pinato DJ. The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liver Int 2019;39(11):2008-23.
Kato A, Tsuji T, Sakao Y, Ohashi N, Yasuda H, Fujimoto T, et al. A comparison of systemic inflammation-based prognostic scores in patients on regular hemodialysis. Nephron Extra 2013;3(1):91-100.
Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'reilly DSJ, Fouliset AK, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2011;104(4):726-34.
Dettorre GM, Dolly S, Loizidou A, Chester J, Jackson A, Mukherjee U, et al. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. J Immunother Cancer 2021;9(3).
Akaike T, Suga M, Maeda H. Free radicals in viral pathogenesis: molecular mechanisms involving superoxide and NO. Proc Soc Exp Biol Med 1998;217(1):64-73.
Jing Liang J, Liu J, Chen Y, Ye B, Li N, Wang X, et al. Characteristics of laboratory findings of COVID-19 patients with comorbid diabetes mellitus. Diabetes Res Clin Pract 2020;167:108351.
Li G, Wu X, Zhou CL, Wang Y, Song B, Cheng X, et al. Uric acid as a prognostic factor and critical marker of COVID-19. Sci Rep 2021;11(1):17791.
Jin Z, Zheng M, Shi J, Ye X, Cheng F, Chen QL, et al. Correlation Analysis Between Serum Uric Acid, Prealbumin Level, Lactate Dehydrogenase, and Severity of COVID-19. Front Mol Biosci 2021;8:615837.
Hu F, Guo Y, Lin J, Zeng Y, Wang J, Li M, et al. Association of serum uric acid levels with COVID-19 severity. BMC Endocr Disord 2021;21(1):97.
Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood 2019;133(1):40-50.
Omrani-Nava V , Maleki I, Ahmadi A , Moosazadeh M, Hedayatizadeh-Omran A, Roozbehet F, et al. Evaluation of Hepatic Enzymes Changes and Association with Prognosis in COVID-19 Patients. Hepat Mon 2020;20(4):e103179.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506.
Ayhan M, Odabas H, Turan N, Ozyukseler DT, Kostek O, Alkan G, et al. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother 2021;33(7):499-508.